Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo Clinic discover important clue to new treatments for lymphoma, breast and colon cancers

24.02.2004


Mayo Clinic researchers discover that key cancer gene cbp doesn’t work alone; Important clue to targeting new treatments for lymphoma, breast and colon cancers



Mayo Clinic cancer researchers have discovered a key partnership between two genes in mice that prevents the development of cancer of the lymph nodes, known as T-cell leukemia or lymphoma.

This first-time finding provides researchers with a promising target for designing new anti-cancer drugs that fight lymphomas, as well as other cancers in which this partnership exists, including breast and colon cancers.


The Mayo Clinic research report appears as the cover story in today’s edition of the journal, Cancer Cell, (http://www.cancercell.org). Jan van Deursen, Ph.D., a specialist in pediatric cancers with the Department of Pediatrics and a member of the Mayo Clinic Cancer Center, led the research team.

According to Dr. van Deursen, the Mayo Clinic cancer research team used specially-bred laboratory mice to demonstrate three things not previously known about the development of these types of cancer. They are the first to:
  • Provide laboratory evidence that the gene CBP is a tumor suppressor -- and that the lack of CBP contributes to the formation of lymphoma.

  • Demonstrate that the absence of CBP works in partnership with low levels of a protein called p27Kip1. When these two conditions are present, lymphoma development accelerates in mice.

  • Discover that two compounds -- Cyclin E and Skp2 -- control p27Kip1 levels.

"We not only found the tumor suppressor, we also showed what other gene defects need to occur in the same cell for cancer to progress," says Dr. van Deursen. "Cancer is not the result of a single defect, but is related to a combination of defects and events," he explains. "To find the best treatment, it’s vital to discover what combinations of changes have occurred with the cell to transform it from a normal cell into a cancer cell."

Lymphoma belongs to the hematologic malignancies group of cancers because it involves blood, bone marrow and lymph nodes. In general, it is one of the more common cancers and it is increasing in the United States. Each year about 50,000 Americans are diagnosed with some form of lymphoma, and another 30,000 die from the cancer.

Background Analogy: Cancer as a River and the Search for its Headwaters

Cancer researchers liken cancer to a river with directional flow. Like a river, cancer flows downstream toward production of disease. What researchers want to find is the upstream headwaters -- the point of origin that eventually leads to cancer.

They look for the earliest "upstream" cellular irregularities that contribute to dangerous "downstream" conditions. In this study, Mayo Clinic researchers discovered a previously unknown early, upstream event in the cancer process -- that the compounds Cyclin E and Skp2 are upstream elements that control the downstream level of p27Kip1. They found that when p27Kip1 levels are low, and when combined with the absence of CBP, conditions favor cancer.

"Low levels of p27Kip1 are often associated with human cancers and with very poor prognosis," says Dr. van Deursen. "We have shown in our research the mechanism by which p27Kip1 gets altered. Now that we know this mechanism, we can design treatments to keep levels of p27Kip1 from going down."

Dr. van Deursen notes that altered levels of p27Kip1 are not the result of a defective gene. Rather, the altered levels are the indirect result of high levels of the upstream molecules, Cyclin E and Skp2.

"If we can prevent these indirect upstream effects from happening, then the undesirable downstream events will not occur," he says.

From this finding, the Mayo Clinic cancer researchers conclude that a cooperative relationship exists between the loss of CBP and depressed levels of p27Kip1 to produce cancer.


A grant to Mayo Clinic from the Department of Defense funded this research study. Researchers from St. Jude Children’s Research Hospital in Memphis, Tenn., also contributed to the investigation.

Mary Lawson | EurekAlert!
Further information:
http://www.cancercell.org
http://www.mayo.edu/
http://www.mayoclinic.com

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

Construction of practical quantum computers radically simplified

05.12.2016 | Information Technology

NASA's AIM observes early noctilucent ice clouds over Antarctica

05.12.2016 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>